Recombinant Human Thrombopoietin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Recombinant Human Thrombopoietin
- DrugBank Accession Number
- DB16364
- Background
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.1,2 This drug is used in the treatment of thrombocytopenia.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- rhTPO
- rHuTPO
- External IDs
- Recombinant Human Thrombopoietin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Recombinant human thrombopoietin has similar biological functions as endogenous thrombopoietin.2 It activates the thrombopoietin receptor MPL.1 This therapy has potential roles in hematopoietic stem and progenitor cell regeneration and is currently being investigated against relapsed immune thrombocytopenia, hematopoietic injury, and acute severe thrombocytopenia in sepsis.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- E2E529W34D
- CAS number
- Not Available
References
- General References
- Wang C, Zhang B, Wang S, Zhang J, Liu Y, Wang J, Fan Z, Lv Y, Zhang X, He L, Chen L, Xia H, Li Y, Pei X: Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation. Sci Rep. 2015 Sep 25;5:12993. doi: 10.1038/srep12993. [Article]
- Zhou Z, Feng T, Xie Y, Huang P, Xie H, Tian R, Qian B, Wang R: The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis. 2019 Sep 6;19(1):780. doi: 10.1186/s12879-019-4388-2. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Thrombocytopenia 1 4 Recruiting Treatment Primary Immune Thrombocytopenia (ITP) 1 4 Recruiting Treatment Thrombocytopenia 1 4 Unknown Status Treatment Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) / Delayed Platelet Engraftment / Myeloablative 1 3 Completed Prevention Sarcomas 1 3 Completed Treatment Hematologic Diseases / Thrombocytopenia 1 3 Completed Treatment Idiopathic Thrombocytopenic Purpura 1 3 Completed Treatment Idiopathic Thrombocytopenic Purpura / Pregnant State 1 3 Completed Treatment Idiopathic Thrombocytopenic Purpura / Purpura 3 3 Not Yet Recruiting Treatment Idiopathic Thrombocytopenic Purpura 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution 15000 iu/1ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 17, 2020 22:51 / Updated on May 05, 2021 20:32